Trinity Biotech Plans 1-for-30 Reverse ADS Split to Regain Nasdaq Compliance

summarizeSummary

Trinity Biotech announced a 1-for-30 reverse ADS split effective July 24, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price rule. The split is a necessary step to avoid delisting amid severe financial distress.

check_boxKey Events · Corporate Governance and Compliance · TRIB

• 1-for-30 Reverse ADS Split Announced

  Effective July 24, 2026, the ADS ratio changes from 1 ADS representing 20 ordinary shares to 1 ADS representing 600 ordinary shares. Every 30 old ADSs will be exchanged for 1 new ADS.

• Nasdaq Compliance at Risk

  The split aims to lift the ADS price above the $1.00 minimum bid requirement. At the current price of $0.2746, the stock is far below the threshold, and delisting would severely limit capital-raising options.

• Financial Distress Backdrop

  Going concern doubts hang over the company, which recently terminated a $25M equity facility and has been relying on highly dilutive financings. The reverse split is a defensive move to preserve its Nasdaq listing.

• No Change to Underlying Business

  The reverse split does not alter the company's market capitalization, operations, or financial condition. It is a mechanical adjustment to the ADS price, with no assurance the higher price will be sustained.

auto_awesomeAnalysis · TRIB · Life Sciences

To push its ADS price above the $1.00 Nasdaq minimum bid requirement, Trinity Biotech is implementing a 1-for-30 reverse ADS split effective July 24, 2026. The stock has been trading near its 52-week low, and with going concern doubts already on the table, delisting is a real threat. While the split mechanically boosts the share price, it does nothing to change the underlying business fundamentals or market capitalization. The move is a survival tactic to maintain the Nasdaq listing—critical for access to capital markets given the company's ongoing financing needs and the recent termination of a dilutive equity facility.